PharmGen Science (004720.KS) Stock Price

PharmGen Science Price

CLOSED
3,050.00KRW-20.00 (-0.65 %)
Market closed

Revenue has compounded at 6.6% per year over the past 19 years to 171.29 B KRW. Earnings per share have declined at 7.7% per year over the last 19 years. PharmGen Science's net margin stands at 1.6%, down from 9.5% several years earlier. The stock trades about 13% above its 52-week low.

PharmGen Science stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of PharmGen Science over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how PharmGen Science stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing PharmGen Science's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

PharmGen Science Stock Price History
DatePharmGen Science Price
7/10/20263,050.00 KRW
7/9/20263,070.00 KRW
7/8/20263,200.00 KRW
7/7/20263,115.00 KRW
7/6/20263,165.00 KRW
7/3/20263,245.00 KRW
7/2/20263,115.00 KRW
7/1/20263,025.00 KRW
6/30/20262,955.00 KRW
6/29/20263,045.00 KRW
6/26/20262,870.00 KRW
6/25/20262,925.00 KRW
6/24/20262,820.00 KRW
6/23/20262,710.00 KRW
6/22/20262,785.00 KRW
6/19/20262,910.00 KRW
6/18/20263,000.00 KRW
6/17/20263,140.00 KRW
6/16/20263,140.00 KRW
6/15/20263,200.00 KRW
6/12/20263,195.00 KRW
6/11/20263,120.00 KRW
6/10/20263,110.00 KRW
6/9/20263,090.00 KRW
6/8/20263,005.00 KRW
6/5/20263,090.00 KRW
6/4/20263,165.00 KRW
6/2/20263,080.00 KRW
6/1/20263,160.00 KRW
5/29/20263,290.00 KRW
5/28/20263,450.00 KRW
5/27/20263,540.00 KRW
5/26/20263,620.00 KRW
5/22/20263,680.00 KRW
5/21/20263,575.00 KRW
5/20/20263,575.00 KRW
5/19/20263,620.00 KRW
5/18/20263,670.00 KRW
5/15/20263,725.00 KRW
5/14/20263,840.00 KRW
5/13/20263,850.00 KRW
5/12/20263,940.00 KRW
5/11/20263,830.00 KRW
5/8/20264,010.00 KRW
5/7/20264,000.00 KRW
5/6/20264,000.00 KRW
5/4/20264,150.00 KRW
4/30/20264,195.00 KRW
4/29/20264,175.00 KRW
4/28/20263,960.00 KRW
4/27/20263,925.00 KRW
4/24/20263,865.00 KRW
4/23/20263,845.00 KRW
4/22/20263,830.00 KRW
4/21/20263,855.00 KRW
4/20/20263,940.00 KRW
4/17/20263,980.00 KRW
4/16/20263,880.00 KRW
4/15/20263,860.00 KRW
4/14/20263,865.00 KRW
4/13/20263,770.00 KRW
4/10/20263,755.00 KRW
4/9/20263,650.00 KRW
4/8/20263,675.00 KRW
4/7/20263,540.00 KRW
4/6/20263,640.00 KRW
4/3/20263,655.00 KRW
4/2/20263,640.00 KRW
4/1/20263,760.00 KRW
3/31/20263,665.00 KRW
3/30/20263,775.00 KRW
3/27/20263,815.00 KRW
3/26/20263,835.00 KRW
3/25/20263,845.00 KRW
3/24/20263,780.00 KRW
3/23/20263,760.00 KRW
3/20/20263,750.00 KRW
3/19/20263,660.00 KRW
3/18/20263,745.00 KRW
3/17/20263,740.00 KRW
3/16/20263,760.00 KRW
3/13/20263,815.00 KRW
3/12/20263,835.00 KRW
3/11/20263,755.00 KRW
3/10/20263,650.00 KRW
3/9/20263,560.00 KRW
3/6/20263,710.00 KRW
3/5/20263,715.00 KRW
3/4/20263,500.00 KRW
3/3/20263,830.00 KRW
2/27/20263,925.00 KRW
2/26/20263,970.00 KRW
2/25/20264,110.00 KRW
2/24/20264,180.00 KRW
2/23/20264,185.00 KRW
2/20/20264,085.00 KRW
2/19/20264,080.00 KRW
2/13/20264,085.00 KRW
2/12/20264,190.00 KRW
2/11/20264,210.00 KRW
2/10/20264,185.00 KRW
2/9/20264,180.00 KRW
2/6/20264,195.00 KRW
2/5/20264,185.00 KRW
2/4/20264,210.00 KRW
2/3/20264,165.00 KRW
2/2/20264,110.00 KRW
1/30/20264,210.00 KRW
1/29/20264,260.00 KRW
1/28/20264,255.00 KRW
1/27/20264,250.00 KRW
1/26/20264,260.00 KRW
1/23/20264,220.00 KRW
1/22/20264,120.00 KRW
1/21/20264,110.00 KRW
1/20/20264,260.00 KRW
1/19/20264,045.00 KRW
1/16/20264,045.00 KRW
1/15/20264,070.00 KRW
1/14/20264,065.00 KRW
1/13/20264,115.00 KRW
1/12/20264,200.00 KRW
1/9/20264,230.00 KRW
1/8/20264,205.00 KRW
1/7/20264,295.00 KRW
1/6/20264,300.00 KRW
1/5/20264,350.00 KRW
1/2/20264,400.00 KRW
12/30/20254,155.00 KRW
12/29/20254,160.00 KRW
12/26/20254,170.00 KRW
12/24/20254,230.00 KRW
12/23/20254,285.00 KRW
12/22/20254,305.00 KRW
12/19/20254,230.00 KRW
12/18/20254,225.00 KRW
12/17/20254,180.00 KRW
12/16/20254,115.00 KRW
12/15/20254,200.00 KRW
12/12/20254,205.00 KRW
12/11/20254,345.00 KRW
12/10/20254,115.00 KRW
12/9/20254,130.00 KRW
12/8/20254,140.00 KRW
12/5/20254,165.00 KRW
12/4/20254,130.00 KRW
12/3/20254,070.00 KRW
12/2/20254,070.00 KRW
12/1/20254,080.00 KRW
11/28/20254,035.00 KRW
11/27/20253,855.00 KRW
11/26/20253,915.00 KRW
11/25/20253,835.00 KRW
11/24/20253,810.00 KRW
11/21/20253,900.00 KRW
11/20/20253,970.00 KRW
11/19/20253,895.00 KRW
11/18/20253,950.00 KRW
11/17/20254,030.00 KRW
11/14/20254,110.00 KRW
11/13/20254,115.00 KRW
11/12/20254,100.00 KRW
11/11/20254,005.00 KRW
11/10/20254,060.00 KRW
11/7/20254,005.00 KRW
11/6/20254,065.00 KRW
11/5/20253,915.00 KRW
11/4/20253,985.00 KRW
11/3/20253,890.00 KRW
10/31/20254,035.00 KRW
10/30/20254,080.00 KRW
10/29/20254,150.00 KRW
10/28/20254,155.00 KRW
10/27/20254,190.00 KRW
10/24/20254,035.00 KRW
10/23/20254,065.00 KRW
10/22/20254,095.00 KRW
10/21/20254,080.00 KRW
10/20/20254,080.00 KRW
10/17/20254,055.00 KRW
10/16/20254,160.00 KRW
10/15/20254,135.00 KRW
10/14/20254,110.00 KRW
10/13/20254,180.00 KRW
10/10/20254,200.00 KRW
10/2/20254,390.00 KRW
10/1/20254,330.00 KRW
9/30/20254,335.00 KRW
9/29/20254,420.00 KRW
9/26/20254,390.00 KRW
9/25/20254,430.00 KRW
9/24/20254,460.00 KRW
9/23/20254,530.00 KRW
9/22/20254,570.00 KRW
9/19/20254,590.00 KRW
9/18/20254,500.00 KRW
9/17/20254,485.00 KRW
9/16/20254,535.00 KRW
9/15/20254,505.00 KRW
9/12/20254,500.00 KRW
9/11/20254,570.00 KRW
9/10/20254,545.00 KRW
9/9/20254,500.00 KRW
9/8/20254,510.00 KRW
9/5/20254,395.00 KRW
9/4/20254,325.00 KRW
9/3/20254,335.00 KRW
9/2/20254,330.00 KRW
9/1/20254,295.00 KRW
8/29/20254,410.00 KRW
8/28/20254,470.00 KRW
8/27/20254,470.00 KRW
8/26/20254,480.00 KRW
8/25/20254,485.00 KRW
8/22/20254,440.00 KRW
8/21/20254,455.00 KRW
8/20/20254,485.00 KRW
8/19/20254,490.00 KRW
8/18/20254,540.00 KRW
8/14/20254,570.00 KRW
8/13/20254,615.00 KRW
8/12/20254,555.00 KRW
8/11/20254,550.00 KRW
8/8/20254,580.00 KRW
8/7/20254,580.00 KRW
8/6/20254,585.00 KRW
8/5/20254,550.00 KRW
8/4/20254,485.00 KRW
8/1/20254,460.00 KRW
7/31/20254,660.00 KRW
7/30/20254,745.00 KRW
7/29/20254,925.00 KRW
7/28/20254,245.00 KRW
7/25/20254,270.00 KRW
7/24/20254,265.00 KRW
7/23/20254,315.00 KRW
7/22/20254,280.00 KRW
7/21/20254,370.00 KRW
7/18/20254,445.00 KRW
7/17/20254,485.00 KRW
7/16/20254,375.00 KRW
7/15/20254,425.00 KRW
7/14/20254,365.00 KRW
Access this data via the Eulerpool API
Get Free API Key

PharmGen Science Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2017
79.89 B KRW
6.01 B KRW
4.32 B KRW
Jan 1, 2018
89.10 B KRW
4.99 B KRW
4.47 B KRW
Jan 1, 2019
95.14 B KRW
1.19 B KRW
302.00 M KRW
Jan 1, 2020
96.61 B KRW
-670.00 M KRW
9.22 B KRW
Jan 1, 2021
109.87 B KRW
-5.04 B KRW
32.47 B KRW
Jan 1, 2022
150.93 B KRW
7.47 B KRW
70.06 B KRW
Jan 1, 2023
166.78 B KRW
9.13 B KRW
6.09 B KRW
Jan 1, 2024
171.29 B KRW
10.64 B KRW
2.79 B KRW

PharmGen Science Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 12, 2026, 9:08 AM
 
REVENUEB KRW
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB KRW
NET INCOMEB KRW
NET INCOME GROWTH%
SHARESM
2009201020112012201320142015201620172018201920202021202220232024
48.7440.0727.9130.2938.9744.2060.4171.5579.8989.1095.1496.61109.87150.93166.78171.29
31.14-17.80-30.338.5328.6513.4336.6518.4411.6711.536.771.5513.7237.3810.502.70
63.8063.4254.7653.7756.3354.0253.5755.8851.6351.8552.9855.4855.3453.8758.6863.07
31.1025.4115.2816.2921.9523.8832.3639.9841.2546.2050.4053.6060.8081.3097.87108.03
-1.95-3.92-8.82-5.23-3.70-4.582.073.454.324.470.309.2232.4770.066.092.79
-82.79101.44124.99-40.71-29.3023.93-145.0967.0125.143.43-93.242,953.64252.05115.79-91.31-54.17
9.006.006.007.008.008.009.0010.0011.0012.0012.0015.0018.6021.5920.8021.78
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales PharmGen Science generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue PharmGen Science retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare PharmGen Science's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares PharmGen Science has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against PharmGen Science's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

PharmGen Science stock margins

The PharmGen Science margin analysis displays the gross margin, EBIT margin, as well as the profit margin of PharmGen Science. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for PharmGen Science.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2017
51.63 %
7.52 %
5.41 %
Jan 1, 2018
51.85 %
5.60 %
5.01 %
Jan 1, 2019
52.98 %
1.25 %
0.32 %
Jan 1, 2020
55.48 %
-0.69 %
9.55 %
Jan 1, 2021
55.34 %
-4.59 %
29.55 %
Jan 1, 2022
53.87 %
4.95 %
46.42 %
Jan 1, 2023
58.68 %
5.47 %
3.65 %
Jan 1, 2024
63.07 %
6.21 %
1.63 %

PharmGen Science Stock Revenue, EBIT, Earnings per Share

The PharmGen Science earnings per share therefore indicates how much revenue PharmGen Science has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2017
7,263.09 KRW
546.45 KRW
392.73 KRW
Jan 1, 2018
7,425.17 KRW
415.50 KRW
372.33 KRW
Jan 1, 2019
7,928.17 KRW
98.92 KRW
25.17 KRW
Jan 1, 2020
6,440.93 KRW
-44.67 KRW
614.80 KRW
Jan 1, 2021
5,907.35 KRW
-270.88 KRW
1,745.65 KRW
Jan 1, 2022
6,990.41 KRW
346.09 KRW
3,244.84 KRW
Jan 1, 2023
8,019.83 KRW
438.88 KRW
292.79 KRW
Jan 1, 2024
7,864.26 KRW
488.66 KRW
128.13 KRW

PharmGen Science business model & stock analysis

PharmGen Science Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

PharmGen Science historical P/E ratio, EBIT multiple, and P/S ratio

PharmGen Science annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

PharmGen Science shares outstanding

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2017
11.00 M Stocks
Jan 1, 2018
12.00 M Stocks
Jan 1, 2019
12.00 M Stocks
Jan 1, 2020
15.00 M Stocks
Jan 1, 2021
18.60 M Stocks
Jan 1, 2022
21.59 M Stocks
Jan 1, 2023
20.80 M Stocks
Jan 1, 2024
21.78 M Stocks

PharmGen Science stock splits

In PharmGen Science's history, there have been no stock splits.

PharmGen Science Dividend History

4 years of dividend payments

YearAnnual DividendYoY ChangePayments
1993150.00KRW 0.0%1×
1992150.00KRW↓ 70.0%1×
1991500.00KRW↓ 16.7%1×
1990600.00KRW—1×
Price targets and forecasts for PharmGen Science are not yet available.

PharmGen Science shareholder structure

% Name
11.36810%
Han (Ui Sang)
Han (Ui Sang)
3.99442%
HD Investment Fund
HD Investment Fund
3.19353%
Kim (Hyeon Suk)
Kim (Hyeon Suk)
2.53975%
Yu (Jae Man)
Yu (Jae Man)
0.95400%
Han (Dae Hui)
Han (Dae Hui)
0.70809%
Dimensional Fund Advisors, L.P.
Dimensional Fund Advisors, L.P.

PharmGen Science Executives and Management Board

UH

Mr. Ui Sang Han

(63)

Chairman · since 2011

Compensation602.50 M KRW
HK

Ms. Hye Yeon Kim

(67)

Co-Chief Executive Officer, Director

HP

Mr. Hui Deok Park

(56)

Co-Chief Executive Officer, Director

GL

Mr. Geun Hyeong Lee

(59)

Vice Chairman · since 2011

NR

Mr. Nam Hyeon Ryu

(58)

Vice Chairman · since 2011

Frequently asked questions about PharmGen Science

Converted at the current exchange rate, the PharmGen Science share trades at 1.77 EUR (3,050.00 KRW).

All fundamentals and in-depth analysis of PharmGen Science

Our stock analysis for PharmGen Science stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PharmGen Science. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

PharmGen Science Stock
PharmGen Science Revenue→
PharmGen Science Stock
PharmGen Science Net Income→
PharmGen Science Stock
PharmGen Science P/E→
PharmGen Science Stock
PharmGen Science P/S→
PharmGen Science Stock
PharmGen Science EBIT→
PharmGen Science Stock
PharmGen Science Dividend→
PharmGen Science Stock
PharmGen Science Directors Dealings→
PharmGen Science Stock
PharmGen Science Stocks→
PharmGen Science Stock
PharmGen Science Market capitalization→
PharmGen Science Stock
PharmGen Science Debt→
PharmGen Science Stock
PharmGen Science Liabilities→
PharmGen Science Stock
PharmGen Science Equity→
PharmGen Science Stock
PharmGen Science AAQS→
PharmGen Science Stock
PharmGen Science Employees→
PharmGen Science Stock
PharmGen Science ROE→
PharmGen Science Stock
PharmGen Science ROA→
PharmGen Science Stock
PharmGen Science ROCE→
PharmGen Science Stock
PharmGen Science News→
PharmGen Science Stock
PharmGen Science Analyst Price Targets→

Health Stocks

Pharmicell CoPharmesis InternationalPharmigenePharmaron Beijing CoPharming GroupPharmaResources (Shanghai) CoPharming GroupPharmaResearch CoPharmosa BiopharmPharmaids PharmaceuticalsPharos IBio CoPharmagreen BiotechAll Stocks A–Z →